In patients with diabetes mellitus (DM) and upper gastrointestinal symptoms, a diagnosis of diabetic gastroparesis is often considered, but population-based data on the epidemiology of diabetic gastroparesis are lacking. We aimed to estimate the frequency of and risk factors for gastroparesis among community subjects with DM.
INTRODUCTION
Gastroparesis is a clinical syndrome characterized by delayed gastric emptying in the absence of mechanical obstruction of the stomach ( 1 ) . Symptoms of gastroparesis are variable but may include early satiety, nausea, vomiting, bloating, and upper abdominal pain. In several studies based on patients seen at tertiary centers, diabetes mellitus (DM) accounted for almost one-third of gastroparesis cases ( 2 -4 ) . Diabetic gastroparesis can result in nutritional compromise, impaired glucose control, and a poorer quality of life, independent of other factors such as age, tobacco and alcohol use, or type of diabetes ( 4 -6 ) .
Th e epidemiology of diabetic gastroparesis is largely unknown. Th e prevalence of gastroparesis is diffi cult to estimate because of the poor correlation of symptoms with gastric emptying ( 3, 7 ) .
Cross-sectional studies ( 8 -10 ) , in most cases using radionuclide techniques to measure gastric emptying, have established that gastric emptying of a solid or nutrient liquid meal is abnormally slow in up to 30 -50 % of outpatients with long-standing type 1 or type 2 DM. However, these studies were all undertaken in referral centers and almost certainly overestimate the prevalence of the condition because of referral and selection bias ( 8 -10 ) . Th e incidence (new onset) of diabetic gastroparesis in the general population has not to our knowledge been reported.
In considering the mechanisms responsible for abnormal gastric motor function in DM, two major factors have been suggested, namely, autonomic neuropathy and sustained hyperglycemia ( 11 -15 ) . Traditionally, gastrointestinal (GI) symptoms in diabetic patients have been attributed to disordered motor function as a
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Th us, we aimed to evaluate the risk of gastroparesis among unselected diabetic subjects in the general community and to evaluate potential risk factors for developing gastroparesis. We hypothesized that long disease duration and autonomic neuropathy would be independent risk factors for developing diabetic gastroparesis.
METHODS

Study setting
Th e Olmsted County, MN population comprises 124,277 persons (2000 US Census data), of whom 89 % are whites; sociodemographically, the community is very similar to the US white population, except for higher education and income levels ( 16 ) . Over 95 % of County residents receive their medical care from one of the two group practices (Mayo Medical Center and Olmsted Medical Center). Th e Mayo Clinic has maintained a common medical record system with its two affi liated hospitals (Saint Marys ' and Rochester Methodist) for over 100 years. Recorded diagnoses and surgical procedures are indexed, including the diagnoses made for outpatients seen in offi ce or clinic consultations, emergency room visits or nursing home care, as well as the diagnoses recorded for hospital inpatients. Under the auspices of the Rochester Epidemiology Project (REP), this indexing and record linkage system was expanded to non-Mayo providers of care including the Olmsted Medical Center. Annually, over 80 % of the entire population is attended by one or both of these two practices, and 96 % of the entire population is seen at least once during any given 3-year period ( 16 ) . Consequently, this medical record linkage system provides what is essentially an enumeration of the population from which random samples can be drawn.
Subjects
Th e present investigation took advantage of a previous study that used REP resources to construct a diabetes prevalence cohort comprising all Olmsted County, MN residents who met National Diabetes Data Group (NDDG) criteria as of 1 January 1995 ( 17 ) , created utilizing a 1990 Rochester diabetes prevalence cohort ( 18 ) and persons assigned a diagnosis of DM or DM-like condition in the REP diagnostic index from 1945 through 1995 ( 19 ) . People known to be deceased or who were younger than 18 years (because gastroparesis is uncommon in this age group ( 21 )) or older than 75 years as of 1 January 1 1995, (because follow-up would be limited) were excluded. For the current study, we used the existing constructed population-based DM prevalence cohort consisting of 269 residents with type 1 DM and 409 residents with type 2 DM for GI symptom survey in 1995 ( 17 ) .
Using the REP database, Olmsted County residents, who were age-and sex-stratifi ed to approximate the age and sex distributions of the residents with type 1 DM and type 2 DM, respectively, were sampled at random. Th e complete (inpatient and outpatient) medical record of each potential control was reviewed to confi rm that they did not meet criteria for DM before 1995 and that they resided in Olmsted County in 1995. A total of 1,374 subjects (269 with type 1 DM, 409 with type 2 DM, 380 controls for type 1 DM, and 355 controls for type 2 DM) were potentially eligible for the current study, but 73 subjects who refused to provide research authorization based on Minnesota statute ( 19 ) and 112 subjects who did not have follow-up data aft er 1995 were excluded ( Figure 1 ). Th us, our fi nal study cohort totaled 1,226 subjects, including 227 patients with type 1 DM, 360 with type 2 DM, 310 controls for type 1 DM, and 329 controls for type 2 DM.
Defi nitions
Diabetes mellitus . Diagnostic criteria for DM closely followed NDDG recommendations ( 20 ) and consisted of two consecutive fasting glucose levels ≥ 140 mg / dl or 1-and 2-h levels ≥ 200 mg / dl obtained during a standard oral glucose tolerance test. Persons who failed to meet these criteria but for whom oral agents or insulin were used for at least 2 weeks also qualifi ed as having diabetes ( 18 ) .
Type 1 or 2 DM ( 17,21 )
. People were classifi ed as having type 1 DM if age at diagnosis of DM (i.e., fulfi llment of NDDG Investigators ′ criteria) is younger than 20 years or if they met the following three criteria: (i) body mass index at diagnosis for men less than 27.8 kg / m 2 and for women less than 27.3 kg / m 2 ; (ii) insulin therapy within 2 weeks of diagnosis and continued for at least 1 year or until death; and (iii) evidence of ketones in serum or urine samples. Conversely, persons who were older than 20 years at diagnosis and did not meet all criteria for type 1 DM were classifi ed as having type 2 DM.
Gastroparesis . Gastroparesis was defi ned as meeting at least one of the following criteria as recorded in the complete (inpatient and outpatient) community medical records ( 21 ): (i) delayed gastric emptying by standard scintigraphy; or (ii) symptoms of nausea and / or vomiting, postprandial fullness, early satiety, bloating, or epigastric pain for more than 3 months plus a physician diagnosis of gastroparesis; or (iii) symptoms of nausea and / or vomiting, postprandial fullness, early satiety, bloating, or epigastric pain for more than 3 months, and food retention on endoscopy or upper GI study.
Ascertainment of gastroparesis
As described in detail elsewhere ( 22 ) , the REP diagnostic index and the database of gastric emptying were used to identify subjects with a clinical diagnosis of gastroparesis or any possible gastroparesis condition during the study period (between 1 January 1996 and 31 December 2006). Out of the total 1,226 subjects 227 patients with type 1 DM, 360 with type 2 DM, and 639 controls (310 for type 1 DM and 329 for type 2 DM), 57 potential gastroparesis cases were identifi ed by the REP diagnostic index ( n = 57), the gastric emptying test database ( n = 3), or both ( n = 3). For confi rming the presence of gastroparesis, one author (R.S.C.) conducted a thorough review of physicians ' notes, medication history, past medical and surgical history, radiological studies
FUNCTIONAL GI DISORDERS
Choung et al.
(including double-contrast upper GI X-ray, small bowel and colon studies, abdominal-pelvic computed tomography scan, and gastric scintigraphy), as well as endoscopy and pathology reports. On the basis of this detailed review, three subjects with a history of gastroparesis before 1995 were excluded. Moreover, 39 additional patients were excluded because of enteric tube feeding (9) , spinal cord problems (5), neurological disease (2), complications aft er gastric surgery (5), other motility problems (5), gastroesophageal refl ux symptoms (3), mechanical obstruction (4), or malignancy (3, esophagus, pancreas, and small bowel); 3 patients had other reasons. Th us, we identifi ed 15 incident gastroparesis cases between 1996 and 2006 ( Figure 2 shows the fl ow sheet for case identifi cation).
Assessment of risk factors
As described in detail elsewhere ( 17 ) , a validated GI questionnaire (BDQ: Bowel Disease Questionnaire) was mailed to all 250 subjects with type 1 DM who had provided the research authorization, with a Flow diagram for assessment of diabetic gastroparesis. In 227 cases with type 1 diabetes mellitus (DM), we identifi ed 20 potential cases from the Rochester Epidemiology Project (REP) who may have had gastroparesis and 10 subjects were confi rmed to have gastroparesis. In 360 cases with type 2 DM, 17 potential gastroparesis cases were identifi ed and 4 cases were confi rmed. Among 639 controls, 20 potential gastroparesis cases were identifi ed, but only 1 subject had confi rmed gastroparesis. GERD, gastroesophageal refl ux disease.
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Gastroparesis in DM response rate of 55 % (138 / 250). Although the survey was also mailed to the other groups, including those with type 2 DM and controls, their data could not be used for assessing risk factors because so few gastroparesis cases developed among those subjects.
Th e survey included questions covering GI tract symptoms, the Somatic Symptom checklist (non-GI symptoms), and symptoms of autonomic and peripheral neuropathy derived from the Neuropathy Symptom Profi le developed by Dyck et al . ( 23 ) . As described in detail elsewhere ( 23 ) , this instrument has been shown to have adequate content, predictive and construct validity in subjects with health, motor neuron disease, diabetic neuropathy, and amyloidosis. Numbness, heat sensation, or a prickly feeling in any part of the body, or weakness in arms or legs was considered indicative of peripheral neuropathy ( 23 ) . Insuffi cient sweating and sweating on the face aft er eating cheese (or gustatory sweating) were suggestive of autonomic dysfunction ( 23 ) . Postural dizziness was not used as an index of autonomic dysfunction because very few subjects (1 % ) reported this, and the rates were comparable between subjects with DM and controls ( 17 ) .
Statistical analysis
Th e subjects with type 1 or 2 DM and controls were considered at risk for gastroparesis from the entry year to diagnosis of gastroparesis, date of death, end of follow-up (31 December 2006), or the date on which participants moved out of the registry ascertainment area. Hazard ratios (HRs) for developing gastroparesis (and 95 % confi dence intervals (CIs)) were calculated from the estimated coeffi cients in Cox proportional hazards regression models. Th e cumulative incidence of gastroparesis in patients with type 1 diabetes was estimated via the Kaplan -Meier method. We could not evaluate risk factors for gastroparesis in patients with type 2 DM vs. corresponding controls because of the small number of gastroparesis " events " . All models were adjusted for potential confounders: age, gender, and / or DM duration. Analyses were done with SAS version 9.1 (SAS Institute, Cary, NC). A signifi cance level of < 0.05 was used, and all tests were two sided. A total of 15 subjects developed gastroparesis through the last follow-up date of December 2006. With 15 events, there was ~ 80 % power (two-sided α = 0.05) to detect a HR of 4.2, or greater, for overall diabetics relative to controls. Among the type 1 diabetics with survey response data, there were four events, and assuming that roughly 50 % of these subjects reported a particular (discrete) risk factor (e.g., nausea), there would be ~ 80 % power (two-sided α = 0.05) to detect a HR of 16 or greater. Table 1 shows the demographic features of 227 subjects with type 1 DM, 360 with type 2 DM, and 639 nondiabetic controls (310 for type 1 DM and 329 for type 2 DM) at baseline in 1995. Duration of disease was associated with type of diabetes ( P < 0.001). Overall, 14 of 587 subjects with type 1 or 2 DM had developed gastroparesis. Over a 10-year follow-up, 10 of 227 subjects with type 1 DM had developed gastroparesis, compared with 4 among 360 subjects with type 2 DM; only 1 subject developed gastroparesis among 639 controls between 1 January 1996 and 31 December 2006. Th e Kaplan -Meier (KM) estimate of the cumulative proportions (95 % CI) developing gastroparesis by 10 years was 5.2 % (95 % CI: 2.0 -8.3) for type 1 diabetics, 1.0 % (95 % CI: 0 -2.1) for type II diabetics, and 0.2 % (95 % CI: 0 -0.5) for controls. In the combined group of diabetics, the Kaplan -Meier estimate for cumulative proportion developing gastroparesis by 10 years was 2.6 % (95 % CI: 1.2 -4.0).
RESULTS
Gastroparesis in subjects with type 1 or 2 DM vs. controls
Th e age-and gender-adjusted HR (relative to controls) for gastroparesis was 33 (95 % CI: 4.0 -274; P = 0.001) in patients with type 1 DM, whereas in patients with type 2 DM the HR was 7.5 (95 % CI: 0.8 -68; P = 0.073). In addition, the risk of developing gastroparesis was signifi cantly greater among patients with type 1 DM compared with type 2 DM (HR: 4.4; 95 % CI: 1.1 -17; P = 0.032).
Predictors for gastroparesis in type 1 DM
Among a total of 138 responders with type 1 DM on the survey, only 4 subjects subsequently developed gastroparesis between 1996 and 2006. Table 2 shows the HRs for gastroparesis according to demographics, GI symptoms, or autonomic / peripheral neuropathy in these subjects. Th e cumulative proportion of gastroparesis at 10 years in younger subjects ( < 40 years) with type 1 DM was 8.5 % (95 % CI: 1.1 -15.4) but in older subjects was 7.2 % (95 % CI: 0. 1 -13,8) . Th e cumulative proportion with gastroparesis was higher in women compared with men, but the diff erence was not statistically signifi cant ( Table 2 ). In addition, the cumulative proportion with gastroparesis was higher in subjects with longer disease duration (more than 20 years) compared with subjects with less disease duration, but this association was not statistically signifi cant either. Adjusting for age, gender, and duration of disease, a signifi cantly increased risk of gastroparesis was observed in subjects with heartburn at baseline (HR: 6.6; 95 % CI: 1.7 -25; P = 0.006), relative to the subjects with no heartburn. However, no other GI symptom, including nausea, vomiting, and abdominal 
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discomfort, was signifi cantly associated with gastroparesis in subjects with type 1 DM. Autonomic neuropathy and symptoms of peripheral neuropathy were also not signifi cantly associated with developing gastroparesis in subjects with type 1 DM ( Table 2 ).
DISCUSSION
Gastroparesis is relatively rare in the general population, and we have previously calculated an age-adjusted annual incidence of just 2.4 / 100,000 for men and 9.8 / 100,000 for women in a US population ( 22 ) . However, DM does appear to increase this risk substantially. In our study, the risk of developing gastroparesis among subjects with type 1 DM was elevated over 30-fold, whereas the risk in subjects with type 2 DM was increased almost 8-fold, relative to age-and sex-matched controls. Moreover, we observed that subjects with type 1 DM were four times more likely to develop gastroparesis than those with type 2 DM, consistent with poorer diabetic control and high rates of autonomic neuropathy that occur in patients with type 1 DM ( 24, 25 ) . A remarkable fi nding of the current study is that the incidence of clinically evident gastroparesis among those with diabetes is still rare. Th e current population-based epidemiological study of diabetic gastroparesis suggests that the impact of diabetes on the likelihood of gastroparesis among community patients may have been previously overestimated because previous work on gastroparesis in subjects with DM were mainly based on upper GI symptoms by surveys, not on actual diagnosis or tests ( 11, 22, 25 ) . Th e reported prevalence of delayed gastric emptying in patients with longstanding diabetes in tertiary hospital settings has ranged from 28 to 65 % ( 10,26 -30 ) , but, to our knowledge, there are no other true population-based studies describing the risk of gastroparesis in unselected diabetic subjects. In the present study, we observed that the cumulative incidence of developing gastroparesis in type 1 DM was 5.2 % over 10 years, whereas the overall cumulative risk in type 2 DM was 1.0 % ; only 0.2 % of controls developed gastroparesis during the follow-up. In a small study from a tertiary hospital setting, Jones et al. ( 6 ) observed that gastric emptying of the solid component was delayed in 10 of 20 patients with DM at baseline, and was delayed in an additional 6 patients at follow-up. By contrast, our study demonstrated a very low incidence of gastroparesis in a relatively large community-based DM population.
In a recent population-based study, Jung et al. ( 22 ) found a distinct female predominance of gastroparesis: Th e incidence and prevalence of gastroparesis in women were four times higher than in men. Our study also showed a female predominance of gastroparesis in subjects with type 1 DM, although this was not statistically signifi cant possibly because of the small sample size and limited statistical power. Other studies have also reported that female gender was associated with delayed gastric emptying in patients with diabetes ( 3, 29 ) . Female hormonal changes might explain this gender bias as premenopausal women on oral contraceptives, pregnant women during labor, and postmenopausal women receiving hormone therapy have developed delayed gastric emptying for both solids and liquids that appear to be reversible ( 31 -33 ) . Another possible explanation is a diff erence in health- care-seeking behavior. It is generally accepted that most functional GI disorders are more common in women than in men, and females with dyspepsia seek health care more frequently than males ( 34 ) .
Other risk factors for diabetic gastroparesis remain poorly defi ned ( 4, 6, 30 ) , although the duration of the disease and the presence of complications, such as retinopathy, neuropathy, and nephropathy, are thought to be potentially important ( 4, 29, 30 ) . We did not fi nd a signifi cant association between DM duration and the development of gastroparesis, and the HR was 0.9 (95 % CI: 0.6 -1.3). In a larger cross-sectional questionnaire study of subjects with DM recruited from outpatient clinics ( n = 209) and the community ( n = 892), Bytzer et al. ( 25 ) showed that coexisting peripheral neuropathy was signifi cantly associated with the development of gastroparesis, but autonomic neuropathy was not. In addition, they showed that poor glycemic control, measured both by selfreport and hemoglobin A1c, was an independent risk factor for upper GI symptoms, but the duration and type of diabetes was not signifi cant ( 25 ) . In a 2-year prospective follow-up study, Quan et al. ( 35 ) observed no clear association between GI symptoms and autonomic neuropathy or glycemic control. Th e current study did not look at whether long-term poor glycemic control associated with the development of complications, such as neuropathy, contributes to the risk of gastroparesis. Further studies on the link between glycemic control and developing the gastroparesis in subjects with diabetes are warranted. However, we did not fi nd any signifi cant association between neuropathy and the development of gastroparesis, although heartburn was a predictor.
Th e current study has several strengths. We undertook a population-based approach, which should have minimized the eff ects of referral bias and improved the generalizability of our results, at least to the US white population, although non-whites are underrepresented in this population ( 18 ) . Th e population at risk was clearly defi ned because they were selected from well-established community cohorts with and without documented DM ( 17 ) . Notably, ascertainment of gastroparesis (gastric emptying database with confi rmed with record review) was based on a community-wide diagnostic index and test results with record review, which has an established track record of accuracy ( 16 ) . Th ere are also some potential limitations of this study, most importantly the limited sample size. Th is was particularly problematic in evaluating potential risk factors for gastroparesis among the subjects with type 1 DM, but we believe these results to be of use in designing future studies of the problem. Also, this was a historical cohort study, and a key issue may be underreporting or underrecognition of gastroparesis because we only identifi ed those who visited a physician for symptoms of gastroparesis. However, our communitywide diagnostic index was designed to be highly sensitive ( 16 ) , and we did undertake a detailed medical record review to confi rm the diagnosis of gastroparesis by an expert. In addition, although validated diagnostic criteria for gastroparesis are lacking, we relied on previously published criteria (21) , but these may have overcalled true gastroparesis and the incidence may be even lower.
In summary, this is to our knowledge the fi rst population-based cohort study to describe the incidence and risk factors for gastroparesis in subjects with DM in the community. An increased
